Class: Dual Cholinesterase Inhibitor FDA Indications: Alzheimer's Dementia, Mild To Moderate Dementia Associated With Parkinson's Disease Off-Label Use: Vascular Dementia
Forms: 1.5, 3, 4.5, 6mg capsule; 2mg/mL po soln; Transdermal–4.6 mg/24 hours or 9.5 mg/24 hours or 13.3 mg/24 hours Dose Range: 3-12 mg/day Starting: Initial Dose: Initiate treatment with 1.5 mg twice a day. Dose Titration: After a minimum of 2 weeks, if tolerated, increase dose to 3 mg twice a day and further to 4.5 mg twice a day and 6 mg twice a day if tolerated with a minimum of 2 weeks at each dose.
Recommend administer with food.
Contraindications: Known hypersensitivity to a specific drug or its derivatives is the only true contraindication. Cautious administration of cholinesterase inhibitors is advised in patients who have a previous history of allergy or adverse reactions to prior cholinesterase inhibitors, severe liver disease, preexisting bradycardia, peptic ulcer disease, current alcoholism, asthma, or chronic obstructive pulmonary disease. Side Effects: weakness/asthenia, nausea, anorexia, vomiting, dyspepsia
t½: 1.5 (1.4-1.7)° TMAX: 0.5-1.7° Substrate of: Hepatic esterases Inhibits: ∅ ; Induces: ∅ Active Metabolites: NAP 226-90
- AChEIs have the potential to interfere with the activity of anticholinergic medications
A synergistic effect may be expected with concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists
- high rate of nausea (47%) and vomiting (31%); dose cautiously to avoid this
displays nonlinear pharmacokinetics
when administered with food, the time to maximum concentration is increased, resulting in a ↓ in Cmax of ∼30%
when switching from oral to patch, 6 mg po ≈ 4.6 mg/24h patch; 6-12 mg po ≈ 9.5 mg/24h patch
PK profile showed that compared with the oral formulation, transdermal patch provides smoother and continuous as well as controlled drug delivery over 24h, thereby resulting in fewer side effects
Category B—No reports describing the use of rivastigmine in human pregnancy have been located. Because of its indication, such reports would be rare. Moreover, the animal data suggest that the risk to the embryofetus is low. Therefore, inadvertent exposure to rivastigmine during pregnancy should not be a reason for pregnancy termination.
No reports describing the use of rivastigmine during human lactation have been located. The molecular weight (about 250 for the free base) and moderate protein binding (about 40%) suggest that the drug will be excreted into breast milk. The very short elimination half-life should decrease the amount of drug available for excretion. The effect of this exposure on a nursing infant is unknown.
Patients with moderate to severe renal impairment may be able to only tolerate lower doses.
Patients with moderate to severe hepatic impairment may be able to only tolerate lower doses.
Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated June 10 2018 15:40:14. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.
Think before you use this website!
Psychopharmacopeia.com includes clinical information intended for use by healthcare professionals. This does not constitute as clinical or professional advice. Physicians and other healthcare professionals should always use their own clinical judgment first and follow laws and guidelines in their own practice jurisdiction. Psychopharmacopeia.com does not give medical advice or diagnostic services. Neither we nor our content providers can guarantee that the content covers all possible uses, directions, precautions, drug interactions, or adverse effects that may be associated with any therapeutic treatments.
Non-health care providers who use this website, please do so at your own risk, and always seek professional medical advice. I have done my best to ensure that the information on this website is reliable, but neither we nor our content providers guarantee the accuracy of the information contained on this site.
Use this site at your own risk. Psychopharmacopeia.com and its hosting provider do not assume any liability or responsibility for damage, injury, or death to you, other persons or property from any use of any ideas, information, or instruction in this website.